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Abstract
In myotonic dystrophy type 1 (DM1), somatic mosaicism of the (CTG)n repeat expansion is age-dependent, tissue-specific
and expansion-biased. These features contribute toward variation in disease severity and confound genotype-to-
phenotype analyses. To investigate how the (CTG)n repeat expansion changes over time, we collected three longitudinal
blood DNA samples separated by 8–15 years and used small pool and single-molecule PCR in 43 DM1 patients. We used the
lower boundary of the allele length distribution as the best estimate for the inherited progenitor allele length (ePAL), which
is itself the best predictor of disease severity. Although in most patients the lower boundary of the allele length distribution
was conserved over time, in many this estimate also increased with age, suggesting samples for research studies and
clinical trials should be obtained as early as possible. As expected, the modal allele length increased over time, driven
primarily by ePAL, age-at-sampling and the time interval. As expected, small expansions <100 repeats did not expand as
rapidly as larger alleles. However, the rate of expansion of very large alleles was not obviously proportionally higher. This
may, at least in part, be a result of the allele length-dependent increase in large contractions that we also observed. We also
determined that individual-specific variation in the increase of modal allele length over time not accounted for by ePAL,
age-at-sampling and time was inversely associated with individual-specific variation in age-at-onset not accounted for by
ePAL, further highlighting somatic expansion as a therapeutic target in DM1.
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Introduction
Myotonic dystrophy type 1 (DM1) (OMIM #160900) is the most
common hereditary muscular dystrophy in adults. It shows a
highly variable phenotype mainly characterized by myotonia,
muscle weakness and wasting, cardiac defects, cataracts and
neurological manifestations (1,2). DM1 is a progressive, multi-
system autosomal dominant disorder that affects individuals
of all ages and both sexes (2). The DM1 mutation was identi-
fied in 1992 as an expansion of an unstable CTG trinucleotide
repeat located in the 3′-untranslated region of the DM1 pro-
tein kinase (DMPK) gene (3–8). The repeat is polymorphic in
the general population ranging from 5 to ∼37 repeats, while
affected patients carry alleles from ∼50 up to several thousand
repeats (4,6,8,9). Expansion size correlates positively with dis-
ease severity and negatively with the age-at-onset, but these
correlations are relatively poor with little predictive value (10–
13). Since its discovery, DM1 mutation has been shown to be
highly unstable and biased toward expansion in the germline,
providing the molecular basis for anticipation (i.e. the increase in
the severity and decrease in the age-at-onset through successive
generations) (14,15). Although parents of both sexes can transmit
DM1, the sex and age of the parent are important in determining
intergenerational amplifications of the mutation (16).
The repeat is also somatically unstable in an expansion-
biased, age-dependent and tissue-specific manner (17–20), with
repeat lengths being much larger in DNA of skeletal muscle
tissue than blood (19,21–24). Molecular diagnosis of DM1 has
traditionally been carried out using southern blot analysis of
restriction-enzyme-digested genomic blood DNA, where the
expanded allele usually presents as a broad smear instead of
a discrete band. It is common practice to report the midpoint
of the smear as the allele size of the patient (4,6,8,10,11,13,25–
30). However, given that somatic mosaicism is expansion-biased
and age-dependent, the number of repeats measured will be
dependent on the age at which the DNA sample was obtained,
confounding genotype-to-phenotype associations (9,31). By
using small amounts of input DNA in small pool-PCR (SP-
PCR), it has been possible to resolve the diffuse smear into
its component alleles (19) and perform more detailed analysis
of somatic mosaicism in DM1. In particular, by estimating
the inherited or progenitor allele length (ePAL), it is possible
to account for the confounding effects of somatic mosaicism
and substantially improve genotype-to-phenotype correlations
(9,31–33). Using SP-PCR data, it has been possible to link
individual-specific variation in the rate of somatic expansion in
blood DNA (after correcting for age-at-sampling and ePAL) with
individual-specific variation in disease severity (after correcting
for ePAL) (9,31).
These data strongly implicate somatic expansion in the
pathogenesis, a notion further supported by the repeat-
stabilizing and disease-moderating impact of variant repeat
interruptions within the DMPK CTG repeat tract (31,33–37) as
well as polymorphisms in the MSH3 DNA mismatch repair gene
(32,38). Given the recent similar findings in Huntington disease
(HD), somatic expansion is being increasingly recognized as
a novel therapeutic target in the repeat expansion disorders
(38–43). As such, detailed analyses of the DMPK CTG repeat
expansion in blood DNA are clearly warranted, in order to
better understand the mutational dynamics and evaluate blood
as a potential surrogate biomarker tissue. Although cross-
sectional studies have been important in defining the basic
features of somatic mosaicism, there are only limited data on the
longitudinal progression of somatic mosaicism over time within
patients (18,44). Here, we sought to provide new insights into
the somatic mutational dynamics of the CTG repeat expansion
during the lifetime of DM1 patients over an 8- to 15-year period.
Results
In order to further investigate the mutational dynamics of the
expanded CTG repeat, we performed SP-PCR on three longitudi-
nal blood DNA samples (time points 1, 2 and 3 (TP1, TP2 and TP3),
obtained eight to 15 years apart) in 43 DM1 patients (Fig. 1). All
participants involved in this study were tested for the presence
of AciI-sensitive variant repeats within the CTG repeat tract, and
none were identified (data not shown). As expected, we observed
that both the range and modal allele length increased over
time (Figs 1 and 2A). We have previously used the approximate
lower boundary of the repeat length distribution to estimate the
inherited progenitor allele length (ePAL), which has proven to be
a highly accurate predictor of age-at-onset (9,31). After indepen-
dently processing all DNA samples, we were able to determine
that the lower boundary observed remained unchanged in 22
patients (51%, 22 of 43) over all three time points (Fig. 1A and B).
In contrast, 21 patients (49%, 21 of 43) showed complex patterns
of allele length distributions over time. Specifically, 11 patients
(26%, 11 of 43) showed no obvious change between TP1 and TP2
but an apparent change between TP2 and TP3 (Fig. 1C). In three
samples (7%, 3 of 43), the lower boundary was not obviously
conserved between TP1 and TP2 but was between TP2 and TP3
(Fig. 1D). In seven patients (16%, 7 of 43), the lower boundary
observed at TP1 was different at TP2 and at TP3 (Fig. 1E). These
data suggest that estimating the PAL is best determined using
the earliest possible blood DNA sample.
In order to further analyze the mutational dynamics of each
DM1 sample over time, we used single-molecule SP-PCR to size
at least 40 de novo expanded alleles per sample per time point (in
total, 23 225 single-molecule products were sized) and performed
a detailed quantitative and qualitative analysis of the somatic
mosaicism over time in all 43 samples. Each sample could be
broadly classified into three groups according to the type of
allele length distributions: group 1, small expansions with clear
expansion bias, but without obvious increase in modal allele
over time (Supplementary Material, Fig. S1A and B); group 2,
moderately sized expansions with clear expansion bias, with
increasing modal allele length but decreasing frequency of the
modal alleles over time (Supplementary Material, Fig. S1C and
D); and group 3, large expansions, where the increase of the
modal allele length was not as evident and the repeat seemed to
be stabilized and/or there was a high frequency of contractions
(Supplementary Material, Fig. S1E and F).
Previously, we have used single-molecule data to quantify
the amount of somatic mosaicism by calculating the degree of
somatic instability (SI) as the range between the 10th and 90th
percentile of the total allele length distribution (9,32,45). This
measure provides an estimate of the degree of variance of the
allele length distribution. An alternative measure of somatic
mosaicism that we have also used is to determine the change
in modal allele length relative to inherited ePAL DM1 (31,32,38).
This measure provides an estimate of the average increase in
repeat length over a given time period. Here, we determined
both measures of somatic mosaicism at each time point (TP1
to TP3). Although measuring two slightly different aspects of
somatic mosaicism, these two measures of somatic mosaicism
are nonetheless highly correlated with each other at all three
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Figure 1. Representative small pool-PCR analyses of six Costa Rican DM1 patients sampled longitudinally at three different time points (TP1, TP2 and TP3 indicated
by age in years). Since the longitudinal samples were collected and processed at different time points, samples were analyzed individually, and each autoradiograph
represents the result at each time point analyzed. For comparisons, individual autoradiographs of each patient were size-matched according to the molecular weight
marker. The approximate lower boundary of the allele length distribution at TP1 was used to estimate the progenitor allele length in DM1 blood DNA, indicated with an
arrowhead at the left-hand side of the gel image. The lower boundary can be conserved through all three time points (A and B), only between two time points (C (TP1
to TP2) and D (TP2 to TP3)) or not obviously conserved through all three time points (E). (F) The change of the total allele length distribution from a skewed, to a more
normal distribution with time. The arrowhead on the right-hand side of each gel image indicates the modal allele length, which as can be seen, increases with time.
Modal allele length was estimated as the densest point of the allele length distribution across all of the replicate SP-PCRs for each participant at each time point. Some
samples with large ePALs (e.g. CR111) showed a high frequency of contractions. The sizes of the molecular weight standard converted into the number of CTG triplet
repeats is shown on the left. The identifier, ePAL size, age-at-onset and the age-at-sampling are shown for each sample. For each sample of the same DM1 patient, five
replicate PCRs were performed with approximately 200–300 pg of DNA.
Figure 2. ‘Spaghetti’ plots for the modal allele length (A), change in modal allele length (B) and the degree of somatic instability (C). The plots show the data for all
samples (each line represents a single DM1 patient) for the modal allele length, change in modal allele length and SI with age. The extremes of each line are time points
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Table 1. Changes in somatic mosaicism over time
Time points Mean increment between
time points
Paired t-test
























82 (SD = 75) 88 (SD = 63) P = 9 × 10−9 P = 2 × 10−11 P = 0.633
Paired t-test




7.72 years (SD = 1.76, range = 4–11 years) 4.05 years (SD = 0.31,
range = 4–6 years)
P = 2 × 10−13
TP = time point; TG = time gap; SD = standard deviation.
TP3, respectively) (Supplementary Material, Fig. S2). As expected,
we also observed significant increases in mean modal length
change between TP1 and TP2 (paired t-test, P = 2 × 10−10) and
between TP2 and TP3 (paired t-test, P = 2 × 10−8) and mean SI
between TP1 and TP2 (paired t-test, P = 9 × 10−9) and between
TP2 and TP3 (paired t-test, P = 2 × 10−11) (Table 1, Fig. 2B and C).
However, despite the fact that time gap 1 (TG1, TP1 to TP2) was
significantly longer than time gap 2 (TG2, TP2 to TP3) (paired t-
test, P = 2 × 10−13) (Table 1), there was no detectable difference
between the change in modal allele length or SI between TG1 and
TG2 (for modal allele length change, P = 0.279; for SI, P = 0.633)
(Table 1).
In order to better understand the dynamics of somatic
mosaicism over the short-to-medium period of time, we
calculated the difference in the modal allele length between
TP1 and TP3 and applied the previously derived multivariate
regression model including age-at-sampling and ePAL (9,32,45),
with the addition of the time interval (TG3 = TP3–TP1). These
analyses revealed that approximately 89% of the variation in
modal allele length change over time could be explained by an
interaction between age-at-sampling, the time interval and ePAL
and sex (Model 1a, Table 2). These results are consistent with
our previous observation of a subtle effect of sex on somatic
mutational dynamics (32). When we split the regression model
between males and females, both models remained significant,
with a slightly better fit for males (r2 = 0.90, Model 1b, Table 2)
than females (r2 = 0.87, Model 1c, Table 2).
Interestingly, in some samples with large expansions, we
observed an apparent accumulation of large contractions (e.g.
Fig. 1B and D). In order to quantify these effects, we used the
single-molecule data to determine the frequency of large con-
tractions (defined as reductions in length of >10% relative to
ePAL). Despite the high level of sampling error for any one
estimate, the proportion of contractions detected was highly
dependent on ePAL (TP1 r2 = 0.25, P = 0.0003, Fig. 3A; TP2 r2 = 0.38,
P = 7 × 10−6, Fig. 3B; TP3 r2 = 0.42, P = 2 × 10−6, Fig. 3C).
Next, we sought to determine if ongoing expansion of the
CTG repeat could explain some of the variation in age-at-onset in
DM1. To this end, we first performed a linear regression analysis
to determine the relationship between ePAL and age-at-onset in
DM1 using the previously described statistical model (9,32). The
linear regression model indicated that the log transformation
of ePAL explained approximately 74% (in a quadratic model)
of the variation in age-at-onset (Model 2a, Table 3). Previously,
we demonstrated that the residual variation in SI was inversely
correlated with the residual variation in the age-at-onset, that
is, DM1 patients with higher-than-average SI had an earlier age-
at-onset than average (9,32). In order to confirm if variation in
the somatic mutational dynamics over time was related with
variation in age-at-onset in DM1 patients, we performed a mul-
tivariate regression analysis that included the residual variation
in modal allele length change over time as an independent
variable. The statistical model showed an improvement of the
fit of the model (r2 = 0.78, with all independent variables being
significant), suggesting a modifying role of the somatic muta-
tional dynamics over time on the age-at-onset in DM1 (Model
2b, Table 3).
Finally, we considered if methylation flanking the CTG
repeat expansion (previously implicated in the congenital
form of DM1, CDM (46–49)) could be acting as a modifier
of the somatic mutational dynamics of the CTG repeat. We
performed a pyrosequencing-based methylation analysis (PMA)
to interrogate multiple CpG sites upstream (11 CpG sites
spanning CTCF-1) or downstream (six CpG sites spanning
CTCF-2) of the CTG repeat (Fig. 4A), in order to determine
the methylation levels and status in PBL DNA samples over
time from all 43 DM1 patients. Samples were considered to be
hypermethylated if the mean methylation levels in either the
region upstream or downstream of the CTG repeat were >10%
(45,50). After processing all samples, we found that the samples
of only three DM1 patients across all three time points (9 of 129
(3 TPs × 43 DM1 patients), 7%) were hypermethylated upstream
of the CTG repeat (Fig. 4B, Supplementary Material, Fig. S3).
Hypermethylation downstream of the CTG repeat spanning
CTCF-2 was only observed in the samples of the same three DM1
patients across almost all three time points (one sample was not
hypermethylated at TP3) (Fig. 4B, Supplementary Material, Fig.
S4). Since most of the samples were not hypermethylated down-
stream of the CTG repeat at TP1 or TP2 and hypermethylation
has previously mainly been observed upstream of the CTG repeat
(45,46,49), we only analyzed downstream methylation at TP3 in
a subset number of DM1 samples (Fig. 4B, Supplementary Fig.
S4). The three DM1 patients displaying hypermethylation were
two CDM and one pediatric case (onset around 2 years of age). In
the three patients with hypermethylation, the absolute levels of
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Table 2. Multivariate regression models for the relationship between estimated progenitor allele length (ePAL), age-at-sampling (ages_TP1), time
(TP1–TP3), sex and modal allele length change over time (MALC, mode TP3–mode TP1)
Model Adjusted r2 P Parameter Coefficient Standard
error
z-statistic P
Model 1a: log(MALC) =β0 + β1
log(ePAL) +β2 log(ePAL)2 +β3




n = 43 DM1 patients
0.887 < 0.001 Intercept β0 -10.37 1.98 -5.2 < 0.001
log(ePAL) β1 11.48 1.36 8.5 < 0.001
log(ePAL)2 β2 -2.30 0.28 -8.4 < 0.001
log(ages) β3 -1.35 0.41 -3.3 0.002
Time β4 -0.14 0.05 -2.5 0.015
Interaction β5 0.04 0.01 2.8 0.009
Sex β6 0.16 0.07 2.4 0.023
Model 1b: log(MALC) =β0 +β1
log(ePAL) +β2 log(ePAL)2 +β3
log(ages) +β4 time +β5
(log(ePAL)∗log(Age)∗time)
males only
n = 22 DM1 patients
0.907 < 0.001 Intercept β0 -5.62 2.96 -1.9 0.075
log(ePAL) β1 10.7 1.73 6.1 < 0.001
log(ePAL)2 β2 -2.35 0.36 -6.6 < 0.001
log(ages) β3 -2.59 0.69 -3.7 0.002
Time β4 -0.41 0.12 -3.4 0.004
Interaction β5 0.10 0.03 3.3 0.004
Model 1c: log(MALC) =β0 +β1
log(ePAL) +β2 log(ePAL)2 +β3
log(ages) +β4 time +β5
(log(ePAL)∗log(Age)∗time)
females only
n = 21 DM1 patients
0.865 < 0.001 Intercept β0 -12.49 3.45 -3.6 0.003
log(ePAL) β1 12.02 2.01 5.9 < 0.001
log(ePAL)2 β2 -2.34 0.42 -5.5 < 0.001
log(ages) β3 -0.58 1.06 -0.6 0.590
Time β4 -0.02 0.11 -0.2 0.848
Interaction β5 0.01 0.03 0.4 0.676
The table shows the squared coefficient of correlation (r2) and statistical significance (P) for each model, and the coefficient, standard error, z-statistic and statistical
significance (P), associated with each parameter in the model. The number of individuals used in each analyses is indicated (n). In the model, age at TP1 was used, and
time was the difference between age at TP1 and TP3.
Figure 3. The proportion of large contractions increases with estimated progenitor allele length. The scatter plots show the proportion of large contractions (defined as
contractions >10% the length of estimated progenitor allele length (ePAL)), plotted against the ePAL at each time point. The error bars are the 95% confidence intervals
for each point estimate. The line represents the line of best fit for a regression analysis for the proportion of large contractions dependent on ePAL: time point 1 (A)
r2 = 0.25, P = 0.0003; time point 2 (B) r2 = 0.38, P = 7 × 10−6 and time point 3 (C) r2 = 0.42, P = 2 × 10−6.
downstream of the CTG repeat expansion (medianupstream = 25.6
versus mediandownstream = 15.105, Mann–Whitney U rank sum
test, P = 0.178, n = 17). In those individuals in which we
observed hypermethylation, there was an apparent negative
relationship between age-at-sampling and hypermethylation
levels upstream and downstream of the CTG repeat (Fig. 4B,
Supplementary Material, Fig. S5).
Discussion
It has been well documented that somatic mosaicism of the DM1
(CTG)n repeat expansion mutation is tissue-specific, expansion-
biased and size- and age-dependent (9,17–21,23,51), all features
that contribute to the observed variation in age-at-onset and the
progressive nature of the disease (9,31,32). However, there is only
limited data regarding the somatic mutational dynamics of the
repeat expansion over time in the soma of DM1 patients. Here,
by using SP-PCR we have performed a detailed qualitative and
quantitative longitudinal analysis of the unstable CTG repeat
over three points in 43 DM1 patients. As previously observed, we
have confirmed that the modal allele length and range of alleles
observed increases over time (18,20,31,44).
Previously, we have also shown that by defining the approx-
imate lower boundary of the allele length distributions, we can
estimate the inherited progenitor allele length (ePAL), and that
by accounting for the confounding effects of age-at-sampling,
this measure is the best predictor of disease severity (9,31–33).
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over time in about 50% of the patients analyzed (Fig. 1). In the
remaining DM1 patients analyzed here, the lower boundary also
increased over time concomitant with an increase in modal
allele length. These results highlight that age-at-sampling in
DM1 patients affects PAL estimation and confirms the value of
sampling patients as early as possible before somatic expansion
drives nearly all alleles beyond the inherited allele length (19,31).
For the purposes of prospective research studies and clinical
trials, it may in some cases prove possible to obtain historical
blood DNA samples taken many years previously for diagnostic
purposes (e.g. (31)).
In order to analyze the dynamics of somatic mosaicism
further, we performed single-molecule SP-PCR to quantify the
degree of somatic instability (range between the 10th and
90th percentile of the allele length frequency distribution thus
derived (9,32,45)) at all three time points. The results confirm
the step-wise gain of small numbers of repeats over time,
exemplified by the shift to the right for allele length distributions
(Supplementary Material, Fig. S1), the increase in modal allele
length and the extent of somatic instability over time (18–20,31)
(Figs 1 and 2, Supplementary Material, Fig. S1). However, contrary
to the previous report by Martorell et al. (18), we observed that
all patients with ePALs between 90 and 200 CTG repeats showed
an increase in the modal allele length and the degree of somatic
instability, even over a period of time as short as 4 years between
samplings. This difference is very likely a consequence of the
more sensitive detection method for measuring the degree of
somatic instability and estimation of the PAL. In DM1 patients
with ePALs < 90 CTG repeats (n = 5), the repeat remained very
stable, with no obvious increases in modal allele length or the
degree of somatic instability larger than 7 CTG repeats over a
period of 10 years. These results indicate that the threshold
over which changes in somatic mosaicism in blood DNA start
to become readily detectable and lead to obvious increases in
modal allele length using agarose gel-based SP-PCR in DM1
patients is between ∼100 and 150 CTG repeats. However, alleles
< 90 repeats are nonetheless detectably unstable, and it is
very likely that using methods more sensitive to very small
length changes, such as high-throughput amplicon sequencing
(40), longitudinal changes in smaller expansions will be
detectable.
In each case the modal CTG repeat length in blood DNA
increased over time, indicating a clear net expansion bias. A sub-
set of cells nonetheless acquired contractions (7.2%, 1691/23225).
Many such contractions (49.6%, 839/1691) were relatively small,
within ≤ 10% of ePAL. Such small contractions may well have
arisen via small length change events that represent the recip-
rocal products of the small expansions that are assumed to
drive net expansions over time (52) and are dependent on DNA
mismatch repair (MMR) proteins (42,43,53). However, over 50% of
the observed contractions were relatively large, > 10% of ePAL.
Such large contractions were clearly much more frequent in
larger alleles with higher ePALs (Fig. 3). Interestingly, a length-
dependent increase in the frequency of somatic contractions
has been observed in a transgenic HD mouse model carrying
relatively large expansions (>300 CAG·CTG repeats) (54). In ani-
mal models with moderately sized CAG·CTG repeat expansions
(<200 repeats), the loss of function of a variety of DNA MMR
genes results in complete stabilization of the repeat (55–60).
However, in studies using DM1 transgenes with 300–400 CTG
repeats, MMR gene knockouts showed an apparent increase in
the frequency of repeat contractions (55,58). Likewise, in both
human fibrosarcoma and induced pluripotent stem cells, knock-
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Figure 4. DNA methylation analysis of CpGs flanking the DM1 (CTG)n repeat. (A) Location of the CTCF-binding sites and CpG sites interrogated flanking the DM1 (CTG)n
expansion. The figure shows part of the sequence of exon 15 of the DMPK gene. There are two CTCF-binding sites (gray) flanking the DM1 CTG repeat (boxed). In bold
and italics, the CpG sites interrogated by PMA at both CTCF sites. In all, we analyzed 11 sites upstream and six downstream of the CTG repeat. The location of the
primers used to analyze both regions is also indicated. (B) Heatmap of methylation levels upstream and downstream of the CTG repeat expansion. The heatmap shows
that hypermethylation was only detected in three patients (with very early age-at-onset) who carry the largest CTG expansions. Methylation levels, measured in 43
DM1 patients, sampled longitudinally three times through their lifetime (TP1, TP2 and TP3), are displayed in a white to red scale (0–100%). The levels shown correspond
to the average methylation from 11 (for CTCF-1) and 6 (for CTCF-2) CpG sites analyzed by pyrosequencing-based methylation analysis (PMA). Gray boxes indicate that
PMA was not carried out for the downstream region at TP3 in most participants. Each column of the heatmap represents the data from a single patient, who have
been arranged in increasing order according to the size of the ePAL. The top-row annotation shows the color-encoded clinical subtype of each patient; the bottom-row
annotation displays the size of the ePAL (53–1189 CTG repeats).
increase the frequency of contractions (61,62). These data indi-
cate that natural DNA repair pathways in mammalian cells can
mediate repeat contractions, appearing to be more important for
larger alleles, and are likely to be at least partially DNA MMR
independent.
Our data on modifiers of somatic mosaicism over time
have confirmed the complex relationship between age and
ePAL, in addition to the time interval between sampling, these
factors overall accounting for ∼ 89% of the observed variance
in the increase in modal allele length between TP1 and TP3
(Table 2, Model 1a), very similar to the variance explained in
our previous cross-sectional analyses (9,32). In addition, these
data suggest subtle differences in the dynamics of somatic
mosaicism between males and females (Table 2, Models 1b, c).
Such an observation is consistent with our previous findings in
the Costa Rican population (32) but is at odds with recent data in
the European OPTIMISTIC cohort where no effect of sex on the
lifetime change in modal allele length was detected (31).
However, these cohorts have notably different recruitment
strategies. The Costa Rican cohort was family based, with all
family members with a positive diagnosis offered the opportu-
nity to participate, including those with very mild symptoms,
and severely affected children. In contrast, OPTIMISTIC was
restricted to individuals with moderate symptoms, and very
mild, and very severe, cases were excluded (31). Because smaller
expansions are more unstable and liable to expand in the male
germline, ascertained DM1 families present with an excess
of mildly affected transmitting grandfathers with relatively
modest expansions (16,29,63). Indeed, although not statistically
significant, in the Costa Rican DM1 cohort analyzed here, there
is an excess of males relative to females (6:2) with ePALs <130
repeats. Additional studies will thus be needed to determine
if apparent sex differences underlying somatic mosaicism in
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the possible confounding effects of the age-at-sampling and
ePAL biases that are inherent in DM1 families (16,29,63).
Although overall changes in modal allele length over time
were well explained by age, ePAL and the time between samples,
visual inspection of the data (e.g. Fig. 2A and B) suggests that the
relative role of ePAL is not a simple linear correlation. Clearly,
small alleles with ePALs < 100 repeats show low or only very
modest detectable increases in modal allele length. Alleles with
ePALs > 150 CTG repeats show clear increases in modal allele
length over time. However, the rate of change of modal allele
length with time does not obviously increase notably beyond
alleles with ePALs >300 repeats (see the broadly parallel slopes
for most of the larger alleles in Fig. 2B). Indeed, when considered
in the context of total allele length, those alleles with the largest
ePALs (top left in Fig. 2A) appear to have a slower relative rate
of increase. These observations were derived by quantifying
somatic instability using SP-PCR, which is ultimately limited
by PCR efficiency (19). It is therefore possible that this is, at
least in part, an artifact of amplification failure of very large
expanded alleles. In order to confirm this observation, it would
be necessary to use a more robust approach to measure very
large expanded alleles, such as PCR-free PacBio sequencing (64)
or optical mapping (65). Nonetheless, a reduction in the relative
rate of expansion for larger alleles could be consistent with the
allele length-dependent increase in contractions that we also
observed and parallel similar non-linear length dependencies of
the rate of expansion in a transgenic HD mouse model (54).
As demonstrated previously in cross-sectional studies,
individual-specific differences in the rate of somatic expansion
are associated with variation in DM1 disease severity not
accounted for by ePAL (9,31,32). Here, we provide evidence that
individual-specific variation in the longitudinal accumulation
of expansion is also associated with variation in age-at-onset
of DM1 (Table 3, Models 2a and 2b), confirming the observation
that DM1 patients with higher-than-average somatic expansion
rates have an earlier age-at-onset than average. Unfortunately,
we do not have detailed longitudinal clinical data for the patients
analyzed in this study; thus, we cannot test directly for an
association between longitudinal changes in disease severity
and the accumulation of expansions. Previously though, it
has been demonstrated in cross-sectional studies that DM1
phenotypes that progressively decline such as muscle strength
(e.g. shoulder abductor strength) and cognitive ability (e.g. trail
making test) are best explained by an age/ePAL interaction
(31,33) and that many progressive phenotypes are also asso-
ciated with individual-specific variation in somatic expansion
rates (31). Given the attractiveness of suppressing somatic
expansion as a therapeutic target (41–43), additional longitudinal
data relating somatic expansion rates and disease progression
over time are clearly warranted, in order to further evaluate
the best time windows for intervention and predict likely
efficacy.
It is apparent that individual-specific variation in the rate
of somatic expansion in DM1 is driven in part by cis-acting
modifiers such as the presence of variant repeats within the
DMPK CTG array (31,33–37) and by trans-acting factors such as
polymorphisms in DNA repair genes (32,38). To investigate if
somatic expansion rates might also be modified by cis-acting
epigenetic factors, we determined if CpG site hypermethylation
in two CTCF binding sites flanking the CTG repeat might con-
tribute to longitudinal changes in somatic mosaicism over time.
Previous studies on methylation of the flanking DNA in DM1
PBL have determined that hypermethylation is present mainly
in DM1 congenital cases (47,48). We also recently showed that
hypermethylation was also present in saliva DNA from con-
genital and very early-onset pediatric cases (45). In agreement
with these studies, we observed hypermethylation in only two
congenital and one pediatric case (with very early age-at-onset).
The other 40 DM1 patients analyzed, all adult-onset cases, did
not show hypermethylation at either TP1 or TP2 (methylation
levels in these patients were <10%). Interestingly, in the three
cases with hypermethylation, we observed an apparent age-
dependent decrease in hypermethylation levels flanking the
CTG repeat (Supplementary Material, Fig. S5). It is well estab-
lished that some loci show age-dependent methylation changes,
both increasing or decreasing depending on the specific locus
(66–68). Further longitudinal studies involving more congenital
and pediatric cases, and using more sensitive methods capable
of quantifying low levels of methylation, will be required to con-
firm age-dependent changes in methylation status, better eval-
uate any role for methylation in modifying somatic mosaicism,
and its potential pathogenic significance.
In conclusion, using a longitudinal analysis, we have con-
firmed that the mutant DM1 CTG repeat continues to expand
throughout the lifetime of an individual. A more accurate predic-
tion of the behavior of the CTG mutational dynamics over time
will require a larger sample size and the development of more
objective methods for determining the PAL, such as might be
achieved using computational modeling (e.g. (52)) and/or access
to very early blood DNA samples (e.g. samples taken at birth for
population screening programs). A greater understanding of the
genotype–phenotype relationship in DM1 should facilitate the
stratification of patients based on the mutational behavior of
their CTG repeat expansion in future clinical trials.
Materials and Methods
Patient population
The ethics committee of the Universidad de Costa Rica approved
the project. All patients signed the informed consent in accor-
dance with the ethical protocols approved by the Ethical Scien-
tific Committee of the Universidad de Costa Rica. Previously, we
had determined the size of the estimated progenitor allele length
(ePAL, the size of the expanded allele transmitted from the
parent to their offspring), the presence/absence of AciI-sensitive
variant repeats, the modal allele length, the degree of somatic
instability, age-at-sampling and age-at-onset in a large cohort
of DM1 patients (9,32), defined here as time point one (TP1).
Subsequently, we obtained additional blood DNA samples from
43 of these DM1 patients (22 males and 21 females) taken at two
additional time points, i.e. time point two (TP2) and time point
three (TP3), separated from 8 to 15 years in total (4 to 11 years
from TP1 to TP2, and 4 to 6 years from TP2 to TP3) (Table 1). Here,
we have now determined the modal allele length and the degree
of somatic instability (SI) at the additional two time points TP2
and TP3. All samples were previously tested for the presence of
AciI-sensitive CCG/CGG variant repeats, and none were detected.
Estimation of the modal allele length and
quantification of somatic instability
By using SP-PCR as previously described (9,19), we were able
to analyze a second and a third blood DNA sample from 43
Costa Rican DM1 patients. SP-PCR was carried out using 200–
300 pg of input DNA per reaction. These data were used to
estimate the lower boundary of the allele length distribution








g/ddaa123/5864792 by guest on 24 July 2020
Human Molecular Genetics, 2020, Vol. 00, No. 00 9
of the allele length distribution at each time point, as previously
described (9,19,31,33). In order to perform a detailed qualitative
and quantitative analysis of the somatic mutational dynamics
over time, we also used single-molecule SP-PCR (using 6–50 pg
of input DNA per reaction) to determine the degree of somatic
instability (difference between the 10th and 90th percentiles of
the allele length distribution as described previously (9)) on each
sample at TP2 and TP3. For this, we sized at least 40 single
molecules per patient per time point (at least 40 single molecules
for patients carrying an ePAL < 70 CTG repeats and at least 100
single molecules for patients carrying an ePAL ≥ 71 CTG repeats)
(23 225 single molecules sized in total). We used UVI BANDMAP
(UVITEC, Cambridge, UK) software to size the SP-PCR products.
Supplementary Material, Table S1 contains clinical data and the
molecular data for all patients at the three longitudinal time
points.
Methylation analysis of CTCF-binding sites by
pyrosequencing methylation analysis (PMA)
Analysis of methylation levels and status of the region flank-
ing the DM1 (CTG)n repeat, including two CTCF-binding sites
(CTCF-1, upstream and CTCF-2, downstream), was carried out
by pyrosequencing-based methylation analysis (PMA) as previ-
ously described (45,50). Briefly, 300 ng of DNA from each DNA
sample was used for bisulfite conversion using the EZ DNA
Methylation-Gold Kit (Zymo Research, Irvine, CA, USA) according
to the manufacturer’s instructions. For each sample, 15 ng of
bisulfite-treated DNA was amplified using 100 pmoles of forward
and reverse primer in a final volume of 25 μL containing 1X Hot
StarTaq Master Mix (Qiagen, Hilden, Germany). PMA was carried
out using the PyroMark Q96 MD platform (Qiagen) and PyroMark
Gold Q96 reagents (Qiagen) according to the manufacturer’s
instructions, using the respective sequencing primer at 0.4 μM
(Fig. 4A). PCR and PMA conditions have been published previ-
ously (45). In total, we interrogated 11 CpG sites upstream of the
CTG repeat, of which seven are located within the CTCF1-binding
site, and six downstream, three of which are located within
the CTCF2-binding site (Fig. 4A). The results were analyzed with
the PyroMark CpG 1.0.11 software (Qiagen), which calculates the
mean methylation percentage (mC/(mC + C)) for each CpG site,
allowing quantitative comparisons. The methylation index (MI)
was calculated as the average value of mC/(mC + C) upstream (11
CpGs) or downstream (six CpGs) the CTG repeat.
Statistical analysis
Paired t-tests, Mann–Whitney U test, multivariate and linear
regression analyses were carried out using the SPSS software
package (v20), STATA (v13) or R (3.6.3) and R Studio (v1.2.5033).
In the regression models (Tables 2 and 3), logarithmic (base
10) transformations and quadratic component of ePAL were
included to normalize the distributions and reflect non-linear
components of the associations, as described previously (9,32).
Values of P < 0.05 were considered significant.
Supplementary Material
Supplementary Material is available at HMG online.
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